NasdaqCM - Delayed Quote • USD
Oncternal Therapeutics, Inc. (ONCT)
At close: June 7 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -3.08 | -2.49 | -10.6 | -9.59 |
| Low Estimate | -3.15 | -3.22 | -12.59 | -10.25 |
| High Estimate | -3.03 | -1.5 | -8.24 | -8.59 |
| Year Ago EPS | -3 | -3.4 | -13.43 | -10.6 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 220k | 220k | 1.2M | 800k |
| Low Estimate | 180k | 180k | 1M | 600k |
| High Estimate | 270k | 270k | 1.39M | 1M |
| Year Ago Sales | 106k | 179k | 785k | 1.2M |
| Sales Growth (year/est) | 107.50% | 22.90% | 52.90% | -33.30% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -3.2 | -2.9 | -3.07 | -2.88 |
| EPS Actual | -3 | -3.4 | -3.11 | -2.83 |
| Difference | 0.2 | -0.5 | -0.04 | 0.05 |
| Surprise % | 6.30% | -17.20% | -1.30% | 1.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -3.08 | -2.49 | -10.6 | -9.59 |
| 7 Days Ago | -3.08 | -2.49 | -10.6 | -9.59 |
| 30 Days Ago | -2.6 | -2.62 | -10.66 | -8.44 |
| 60 Days Ago | -2.88 | -2.84 | -11.52 | -10.25 |
| 90 Days Ago | -3.11 | -3.09 | -12.03 | -11.22 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 2 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ONCT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -2.70% | -- | -- | 9.10% |
| Next Qtr. | 26.80% | -- | -- | 11.50% |
| Current Year | 21.10% | -- | -- | 5.70% |
| Next Year | 9.50% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 0.00% | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/31/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/13/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/15/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/29/2024 |
Related Tickers
VINC Vincerx Pharma, Inc.
0.7120
-1.26%
CRVS Corvus Pharmaceuticals, Inc.
2.0300
-3.33%
CRIS Curis, Inc.
8.84
-8.49%
APTO Aptose Biosciences Inc.
0.9200
-2.09%
APVO Aptevo Therapeutics Inc.
0.7911
-6.71%
AKTX Akari Therapeutics, Plc
2.2301
+1.83%
CNTA Centessa Pharmaceuticals plc
8.80
-1.35%
MREO Mereo BioPharma Group plc
3.4200
-0.58%
ELTX Elicio Therapeutics, Inc.
7.83
-3.09%
LPTX Leap Therapeutics, Inc.
2.2400
-0.44%